GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties.
Share This Blog
Ready-to-post copy includes the blog link.
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties. Read the full IIPLA blog post: https://iipla.org/blog/gsk-gains-370-million-upfront-reduced-royalties-in-curevac-mrna-patent-settlement-agreement-with-pfizer-biontech